Summary We have evaluated the prognostic value of tumour-associated trypsin inhibitor (TATI) 
There is a great need for biochemical markers which could reliably reveal the aggressiveness of ovarian tumours before therapy. Such markers could aid clinicians in identifying patients in whom it would be wise to abstain from extensive cytoreductive surgery. CA 125 in serum is a sensitive marker for diagnosis and follow-up of ovarian cancer (Bast et al., 1983) , but the preoperative CA 125 level does not predict prognosis (Makar et al., 1992) . However, rapid normalisation of the CA 125 level after surgery correlates with a good prognosis (Rosen et al., 1990) . Patients with elevated serum CA 125 values 3 months after surgery have a 3.1-fold risk of dying of ovarian cancer compared with patients with normal values (Sevelda et al., 1989) . However, this information is available only after therapy.
Another potentially useful marker for ovarian cancer, tumour-associated trypsin inhibitor (TATI) (Stenman et al., 1982) , is most specific for mucinous tumours, being elevated preoperatively in approximately half of the patients already in stage I disease (Halila et al., 1988; Mogensen et al., 1990) . However, TATI is also elevated at advanced stages of other types of ovarian cancer (Huhtala et al., 1983; Halila et al., 1988; Mogensen et al., 1990 (Bast et al., 1983; Halila et al., 1986) values greater than 35 U ml-' were considered elevated. TATI was measured by radioimmunoassay using reagents from Orion Diagnostica as previously described, and levels exceeding 22 jig 1-were considered elevated (Stenman et al., 1982) .
Statistical analysis was performed using BMDP programs (Dixon, 1981) . Survival curves were calculated with the BMDP1L program and survival analysis with covariates (Cox model) with the BMDP2L program. The Mantel-Cox test was used for calculating statistical significance of survival differences.
Results
Preoperatively, serum CA 125 levels ranged from 47 U ml' to 188,000 U ml-' (mean 4,542 U ml-'). Twenty-seven (41%) women had elevated preoperative TATI levels ranging from 22.4Lgl-' to 389 igl-l (mean 87.3gAgl-') and in 39 the levels were normal ranging from S to 22 tg ll (mean 12.5ftgl-'). The frequency of elevated TATI levels in relation to stage, histological type and grade, and size of residual tumour is shown in Table I .
The magnitude of the preoperative CA 125 elevation did not predict survival: high levels were actually associated with a lower risk, but the difference was not significant (Table II) . In contrast, patients with high preoperative TATI levels had significantly worse cumulative 5 year survival than did patients with normal preoperative TATI levels (P = 0.002) (Figure 1 (Table II) .
In a subgroup of 25 women the CA 125 and TATI levels were determined 3 months after primary surgery. Three months after operation and three courses of chemotherapy 11 patients had an elevated value of either marker. Six had elevated CA 125 levels (mean 400 U ml-', range 38-1,685 U ml-'), and six (three with initial high TATI) had high TATI levels ranging from 25 to 70 tg 1' (mean months after surgery (n = 14) had a cumulative 5 year survival of 52% as compared with 9% in the patients with elevated CA 125 or TATI levels 3 months post-operatively. All patients with 3 months' TATI elevation died within 36 months after surgery, and they had a 6.1-fold (95% CI 2.0-19.0) relative risk of death. Those with TATI and/or CA 125 elevation had a 2.5-fold (95% CI 1.5-4.2) risk of death, and those with only CA 125 elevated had a 2.8-fold risk of death (95% CI 0.9-8.3) compared with patients with normal marker levels.
Discussion
The majority of patients with ovarian cancer are diagnosed at stage III and IV when the disease often cannot be con- trolled by surgery or cytotoxic regimens, thus the 5 year survival is only 23% in stage III and 8% in stage IV patients (Pettersson, 1991) . In these patients a reliable biochemical marker predicting the outcome prior to primary surgery would be valuable for making treatment decisions. In concert with earlier studies (van der Burg et al., 1988; Sevelda et al., 1989; Mogensen, 1992) . The target protease of TATI is tumour-associated trypsin (Koivunen et al., 1989) , which can participate in the protease cascade associated with invasive tumours . TATI and tumour-X 1190 P. VENESMAA et al. associated trypsin are usually expressed simultaneously. Thus a high preoperative TATI level may reflect the proteolytic activity and invasiveness of the tumour . This would explain the correlation between elevated TATI levels and a poor prognosis.
Earlier studies have shown that the CA 125 level 3 months after surgery correlates strongly with survival (Lavin et al., 1987; Sevelda et al., 1989; Mogensen, 1992) . Our study suggests that in patients with advanced disease the TATI level before therapy has a predictive value similar to that of CA 125 3 months after therapy. In addition, all patients with high TATI levels 3 months post-operatively died within 36 months. The prognosis was best if both CA 125 and TATI were normal 3 months post-operatively.
Our results suggest that determination of TATI before therapy and the combined determination of TATI and CA 125 3 months after surgery can be used as an aid for making treatment decisions in patients with advanced ovarian cancer.
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